LIXTE Biotechnology plans to invest 25% of its treasury in Bitcoin and other cryptocurrencies

LIXTE Biotechnology Holdings, a biopharmaceutical company, announced today that its board of directors has approved a strategic capital allocation plan to invest up to 25% of its treasury in cryptocurrencies, including Bitcoin and other digital assets. The specific transaction size and timing will be determined based on market conditions and strategic considerations.